

Cover Story
A move by Genentech has eliminated discounts and rebates hospitals receive when they purchase three of the company's top-selling infused cancer drugs.
By Matthew Bin Han Ong
By Matthew Bin Han Ong
In Brief


Funding Opportunities
Trending Stories
- The faces of RIF: Staff members of NCI’s dissolved communications team gather for a farewell group photo
- A farewell post by an unidentified NCI employee triggers an accusation of “undermining the Trump administration”
- George Sigounas named the first-ever chief science advisor at NCI
- NIH eliminates the NCI Board of Scientific Advisors
Over its 28 year history, BSA shaped NCI-funded extramural science - Makary: Level of evidence is an artificial and dogmatic construct
- Reimagining cancer care for a new generation of patients